drugset / Trial / NCT05257018
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
NaSingle-groupOpen-labelTreatment
Summary
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.
Timeline
- Start
- 2022-02-26
- Primary completion
- 2026-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 35 mg/m2 | — |
| Subject | Methotrexate | Small molecule | 12 mg | Intrathecal |
| Subject | Prednisone | Other / unclassified | 50 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Background | DXM | Unknown | 5 mg | — |